Prestige Consumer Healthcare (NYSE:PBH) Releases FY 2023 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH – Get Rating) issued an update on its FY 2023 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $4.18-$4.23 for the period, compared to the consensus estimate of $4.25. The company issued revenue guidance of $1.12 billion-$1.13 billion, compared to the consensus revenue estimate of $1.11 billion.

Shares of PBH stock opened at $55.63 on Thursday. Prestige Consumer Healthcare has a one year low of $46.31 and a one year high of $63.83. The company’s 50-day moving average is $54.62 and its 200 day moving average is $57.72. The company has a market capitalization of $2.79 billion, a price-to-earnings ratio of 13.77, a price-to-earnings-growth ratio of 1.60 and a beta of 0.58. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.25 and a current ratio of 2.04.

Prestige Consumer Healthcare (NYSE:PBH – Get Rating) last posted its earnings results on Thursday, May 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.02. The business had revenue of $266.94 million for the quarter, compared to analysts’ expectations of $258.25 million. Prestige Consumer Healthcare had a net margin of 18.90% and a return on equity of 14.08%. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.79 EPS. As a group, research analysts predict that Prestige Consumer Healthcare will post 4.27 earnings per share for the current fiscal year.

Several equities analysts have issued reports on PBH shares. StockNews.com initiated coverage on shares of Prestige Consumer Healthcare in a research note on Thursday, March 31st. They set a buy rating on the stock. Jefferies Financial Group upgraded shares of Prestige Consumer Healthcare from a hold rating to a buy rating and increased their price objective for the stock from $65.00 to $70.00 in a research note on Tuesday. Finally, Oppenheimer upgraded shares of Prestige Consumer Healthcare from a market perform rating to an outperform rating and set a $63.00 price objective on the stock in a research note on Monday. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of Buy and an average price target of $76.40.

Large investors have recently modified their holdings of the company. LPL Financial LLC increased its holdings in Prestige Consumer Healthcare by 63.5% in the 3rd quarter. LPL Financial LLC now owns 13,028 shares of the company’s stock worth $735,000 after acquiring an additional 5,062 shares in the last quarter. Citadel Advisors LLC increased its holdings in Prestige Consumer Healthcare by 167.6% in the 4th quarter. Citadel Advisors LLC now owns 68,460 shares of the company’s stock worth $4,152,000 after acquiring an additional 42,875 shares in the last quarter. CIBC World Markets Inc. increased its holdings in Prestige Consumer Healthcare by 8.8% in the 4th quarter. CIBC World Markets Inc. now owns 4,387 shares of the company’s stock worth $266,000 after acquiring an additional 353 shares in the last quarter. Legal & General Group Plc increased its holdings in Prestige Consumer Healthcare by 3.1% in the 4th quarter. Legal & General Group Plc now owns 143,042 shares of the company’s stock worth $8,676,000 after acquiring an additional 4,275 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC increased its holdings in Prestige Consumer Healthcare by 19.7% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 6,700 shares of the company’s stock worth $407,000 after acquiring an additional 1,105 shares in the last quarter.

Prestige Consumer Healthcare Company Profile (Get Rating)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Further Reading